Page last updated: 2024-12-06

pd 131628

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PD 131628: CI-990 is L-alanylamide prodrug of PD-131628; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72448
CHEMBL ID51678
SCHEMBL ID9838735
MeSH IDM0186665

Synonyms (21)

Synonym
127967-03-7
1,8-naphthyridine-3-carboxylic acid, 7-[(3s)-3-amino-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-
pd131628-0002b
pd131628 (hydrochloride)
7-[(3s)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
ci-990 (hydrochloride)
pd 131628
CHEMBL51678
1,8-naphthyridine-3-carboxylic acid, 7-((3s)-3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-
pd-131628
unii-ys492l6chp
ys492l6chp ,
(s)-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
pd131628 ,
1,8-naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, (s)-
SCHEMBL9838735
DTXSID9074486
(s)-7-(3-aminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
7-((3s)-3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
AKOS040753444
PD161111

Research Excerpts

Overview

PD 131628 is a new aminopyrrolidine-substituted fluorocyclopropyl naphthyridine quinolone. It possesses high in vitro activity against a wide spectrum of bacterial species.

ExcerptReferenceRelevance
"PD 131628 is a new aminopyrrolidine-substituted fluorocyclopropyl naphthyridine quinolone which possesses high in vitro activity against a wide spectrum of bacterial species. "( In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.
Cohen, MA; Domagala, JM; Heifetz, CL; Huband, MD; Mailloux, GB; Roland, GE; Yoder, SL, 1991
)
2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID164720In vitro for antibacterial activity against Pseudomonas aeruginosa1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID125255In vitro for antibacterial activity against Morganella morganii1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID201951In vitro antibacterial activity against gram positive Streptococcus pneumoniae SV-1.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID21308Solubility (at pH 4)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID201273In vitro antibacterial activity against gram positive Staphylococcus aureus H-228.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID67225In vitro for antibacterial activity against Enterococcus faecalis1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID70583In vitro for antibacterial activity against Escherichia coli1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID202109In vitro antibacterial activity against gram positive Streptococcus pyogenes C-203.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID21312Aqueous solubility1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID133974In vivo potency against acute systemic infection in mouse caused by Streptococcus pyogenes C-203 on subcutaneous injection1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID133965In vivo potency against acute systemic infection in mouse caused by Pseudomonas aeruginosa UI-18 on oral administration by gavage.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID133960In vivo potency against acute systemic infection in mouse caused by Escherichia coli Vogel on oral administration by gavage.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID152317In vitro antibacterial activity against gram negative Providencia rettgeri M-1771.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID65042In vitro concentration inhibiting DNA gyrase induced cleavage in Escherichia coli H560.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID40338In vitro for antibacterial activity against Bacillus fragilis.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID133966In vivo potency against acute systemic infection in mouse caused by Pseudomonas aeruginosa. UI-18. on subcutaneous injection.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID21310Aqueous solubility1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID133968In vivo potency against acute systemic infection in mouse caused by Streptococcus pneumoniae SV-1 on oral administration by gavage.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID205392In vitro for antibacterial activity against Serratia marcescens1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID65233In vitro antibacterial activity against gram negative Escherichia coli Vogel.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID64389In vitro antibacterial activity against gram negative Enterobacter cloacae MA 2646.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID162741In vitro for antibacterial activity against Proteus mirabilis1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID201409In vitro antibacterial activity against gram positive Staphylococcus aureus UC76.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID68179In vitro for antibacterial activity against Enterobacter cloacae1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID133962In vivo potency against acute systemic infection in mouse caused by Escherichia coli vogel on subcutaneous injection.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID151528In vitro antibacterial activity against gram negative Pseudomonas aeruginosa UI-18.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID94148In vitro antibacterial activity against gram negative Klebsiella pneumoniae. MGH-21992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID133972In vivo potency against acute systemic infection in mouse caused by Streptococcus pyogenes C-203 on oral administration by gavage1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID210197Antibacterial activity against Streptococcus pneumoniae1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID133970In vivo potency against acute systemic infection in mouse caused by Streptococcus pneumoniae SV-1 on subcutaneous injection.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID21306Solubility (in 0.1 N HCl)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
AID205821Antibacterial activity against Staphylococcus aureus1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID95532In vitro for antibacterial activity against Klebsiella pneumoniae1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.
AID65397In vitro antibacterial activity against gram positive Enterococcus faecalis MGH-2.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's27 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.98 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]